Evidence map›Paper›PMID 37999235›Full record

ArticleMetabolites2023

Matrix Selection for the Visualization of Small Molecules and Lipids in Brain Tumors Using Untargeted MALDI-TOF Mass Spectrometry Imaging.

Tianyao Lu, Lutz Freytag, Vinod K Narayana, Zachery Moore, Shannon J Oliver, Adam Valkovic, Brunda Nijagal, Amanda L Peterson, David P de Souza, Malcolm J McConville and 3 more

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. A perioperative study of Safusidenib in patients withFuture oncology (London, England) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Tianyao LuPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia.
Lutz FreytagPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia.ORCID 0009-0009-9256-6127
Vinod K NarayanaMetabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia.ORCID 0000-0003-3980-7496
Zachery MoorePersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia.ORCID 0000-0002-0898-0483
Shannon J OliverPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia.
Adam ValkovicPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia.
Brunda NijagalMetabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia.
Amanda L PetersonMetabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia.
David P de SouzaMetabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia.ORCID 0000-0002-7225-2632
Malcolm J McConvilleMetabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia.ORCID 0000-0002-7107-7887
James R WhittlePersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia.
Sarah A BestPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia.ORCID 0000-0002-4232-9432
Saskia FreytagPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia.
The University of Melbourne · AUWalter and Eliza Hall Institute of Medical Research · AU

Funding

Cancer Australia 2003127Carrie's Beanies 4 Brain Cancer NANational Health and Medical Research Council GNT1184421Victorian Cancer Agency MCRF22003Victorian State Government Operational Infrastructure Support and Australian Government NHMRC Independent Research Institutes Infrastructure Support Scheme NA
6 · The paper itself

Abstract

Matrix-assisted laser desorption/ionization mass spectrometry imaging allows for the study of metabolic activity in the tumor microenvironment of brain cancers. The detectable metabolites within these tumors are contingent upon the choice of matrix, deposition technique, and polarity setting. In this study, we compared the performance of three different matrices, two deposition techniques, and the use of positive and negative polarity in two different brain cancer types and across two species. Optimal combinations were confirmed by a comparative analysis of lipid and small-molecule abundance by using liquid chromatography-mass spectrometry and RNA sequencing to assess differential metabolites and enzymes between normal and tumor regions. Our findings indicate that in the tumor-bearing brain, the recrystallized α-cyano-4-hydroxycinnamic acid matrix with positive polarity offered superior performance for both detected metabolites and consistency with other techniques. Beyond these implications for brain cancer, our work establishes a workflow to identify optimal matrices for spatial metabolomics studies.

Indexed as

atmospheric pressurebrain cancergliomaMALDI-TOFmatrix selection

Identifiers

PMID37999235
PMCPMC10673325
OpenAlexW4388540723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.